Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: CI stock price vs FAST: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at FAST's multiple
Needs FAST P/E.
Implied fair value · at CI's multiple
Needs CI P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
The Cigna Group · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
FASTENAL CO · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
UNITEDHEALTH GROUP INC
CI vs UNH
CVS HEALTH Corp
CI vs CVS
HUMANA INC
CI vs HUM
CENTENE CORP
CI vs CNC
WEST PHARMACEUTICAL SERVICES INC
CI vs WST
BAXTER INTERNATIONAL INC
CI vs BAX
MSC INDUSTRIAL DIRECT CO INC
CI vs MSM
APPLIED INDUSTRIAL TECHNOLOGIES INC
CI vs AIT
HOME DEPOT, INC.
CI vs HD
LOWES COMPANIES INC
CI vs LOW
W.W. GRAINGER, INC.
CI vs GWW
WESCO INTERNATIONAL INC
CI vs WCC
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe CI can sustain double-digit revenue growth while gradually improving margins and managing leverage, then CI looks attractive versus FAST on a relative valuation basis because it trades at much lower P/E, P/S, and EV/EBITDA multiples.
CI trades at a deep discount to FAST on earnings, sales, and EV-based multiples despite meaningful revenue scale. The gap is especially wide on P/S and EV/EBITDA, suggesting the market is assigning FAST a much higher quality and profitability premium.
Supporting Metrics
